Background {#s1}
==========

Asthma is a common inflammatory disorder of the lungs and is often characterized by reversible airflow obstruction and bronchospasm. Allergic asthma is a main threat to public health as it perturbs children\'s respiratory system. More than 300 million people worldwide have allergic asthma ([@B1], [@B2]). According to the data from the World Health Organization (WHO), asthma affects most children, and the number is expected to increase to 400 million in 2025 ([@B3]). With the development of society and industrialization, the incidence and mortality of allergic asthma in children have been increasing. Approximately 30--90% of children with allergic asthma have allergic rhinitis (AR) ([@B4]). AR is one of the related factors in the pathogenesis of allergic asthma, which leads to a direct result of asthma onset ([@B5]). With their similarities in etiology, location, pathogenesis, and pathophysiology, both AR and allergy asthma should be treated together ([@B6]). Seasonal perennial allergens, such as grass, trees, pollen, house dust (HD), mold, and animal fur, can often cause allergic asthma in children ([@B7], [@B8]). In allergic patients, respiratory allergies often lead to systemic allergies. In nasal allergic inflammation, Th1, Th2, and Th17 cells migrate into the bone marrow, stimulating the production of inflammatory cells, mast cells, IL-5, IL-13, IL-17, IL-22, and IL-33 ([@B9]). Inflammatory cells and cytokines enter the nasal mucosa and lungs, triggering respiratory airway inflammation and causing allergic symptoms ([@B10]). At the same time, they can also increase the expression of adhesion molecules in the nasal and bronchial mucosa, thereby aggravating respiratory allergies ([@B11]).

Studies have shown that eosinophils and mast cells play important roles in the pathogenesis of allergic asthma ([@B12]). Th2-like cytokines are mainly secreted by T cells and regulate asthma airway inflammation. T cells and interleukins have been found to play an important role in the progression of allergic asthma ([@B13]).

The regulatory T cell (Treg) is a subpopulation of T cells that regulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disorders. An earlier report found decreased Treg cells in patients with asthma, and there was a significant correlation between change in airway Tregs cells and asthma. Improving Treg cells may be a novel strategy in the prevention of asthma and other allergic disorders ([@B14]). CD4^+^CD25^+^ Treg cells are a unique population of Treg cells that can independently modulate adaptive and innate autoimmune responses ([@B15]). Foxp3 is a cell marker of CD4^+^CD25^+^ Treg cells and is closely related to the differentiation and function of regulatory Treg cells ([@B16], [@B17]), which can regulate the immune responses. In the pathogenesis of asthma, Treg cells secrete a variety of cytokines that can suppress the proliferation of T cells and the synthesis of IgE through the transmission of inflammatory cells, such as IL-10 and TGF-β. In different stages of allergic asthma, the analysis of the effects of cytokines and chemokines becomes very important for asthma prevention and treatment.

*Astragalus*, a large genus of herbs, belongs to the legume family Fabaceae and has potent immune boosting and health-promoting properties ([@B18], [@B19]). *Astragalus membranaceus* (AM) has been widely used for thousands of years in China to treat asthma. Animal model tests showed that the extracts of AM can increase the levels of CD4^+^ CD25^high^ Treg cells and Foxp3 mRNA expression in an asthmatic animal model ([@B20]). *Astragalus* was further found to prevent the recurrence of asthma by modulating Th1/Th2 cytokines in asthmatic children ([@B21]). *Astragalus* oral solution (AOS) is made by the Affiliated Nanjing Hospital of Nanjing Medical University, and one of active ingredients is Astragaloside A, which regulates immune responses. Despite the high efficacy of AOS, little is known about the changes of IL-10, TGF-β, Th1, and Th2 cytokines, and CD4^+^CD25^high^CD127^low^ Treg cells in the children with allergic asthma. Children with allergic asthma were recruited at our hospital from 2016 to 2017, and treated by using AOS. Related indicators and immunological changes were examined to evaluate the value of AOS treatment for the children with allergic asthma.

Materials and methods {#s2}
=====================

Materials
---------

Astragaloside A was purchased from China Pharmaceutical and Biological Laboratory (lot number 11078-200703, Beijing, China). AOS was purchased from Nanjing Hospital of Traditional Chinese Medicine (patches numbers: 100234,100406, 100609, 100815, 100987, and 101009; Nanjing, China). AOS was prepared as follows: AM slices were dried to a constant weight, 450 g. After soaking in 5 liters of distilled water overnight, the main ingredients of AM were extracted by using the ultrasonic constant temperature ultrasonic extractor (Cat. No., Scientz-5TQL4, Ningbo Scientz Biotech., Ningbo, China) twice. The first extract was obtained at 30 min (1000 W), and the second tract at 45 min and 50°C, and the extracts were concentrated to 450 mL. The extracts were further centrifuged at 12,000 × *g* for 30 min, and supernatants were filtered through a 10 kDa membrane (Millipore, Bedford, MA, USA).

Chromatographic conditions
--------------------------

The HPLC system consisted of a Kromasil C18 column (4.6 × 200 mm, id 5 μm) with a guard column (10 × 4.6 mm, id 5 μm) (Waters Chromatography Division of Millipore Corp., Milford, MA, USA), a Waters 515 HPLC Pump, a full-wavelength UV detector, a Waters 717 plus autosampler injector and an Empower workstation. The mobile phase was composed of acetonitrile-water (35:65, v/v), the determination wavelength was 203 nm, and the column temperature was 30°C. All reagents were of chromatographic grade. To achieve the baseline separation and accurate quantitative analysis, the theoretical plate number of Astragaloside A was not less than 3,000.

Measurement of astragaloside A in AOS
-------------------------------------

One-milliliter of AOS was added to a 10 mL volumetric flask and extracted twice with petroleum. The petroleum ether extract was discarded, and the lower solution was extracted four times with saturated n-butanol (20, 15, 15, and 10 mL). The combined n-butanol solution was washed with 5% sodium bicarbonate solution twice, each for 30 mL. The washings were discarded and n-butanol solution was collected, and evaporated to dry. The residue was dissolved in 10-mL ethanol. Approximately 0.05 g Astragaloside A standard was added to a 25 mL volumetric flask, and ethanol was added to achieve 1.967 mg/mL Astragaloside A as a reference. A series of the stock solution (0.2, 0.4, 0.6, 0.8, and 1.0 mL) was added to 10 mL volumetric flask, and ethanol was added to achieve a series of Astragaloside A standards with different concentrations (0.0393, 0.0786, 0.118, 0.157, 0.196 mg/mL). Ten microliter of solution was injected into HPLC and the peak area of Astragaloside A was determined. The measurements were repeated twice. The peak area was used as the ordinate, Astragaloside A concentration was used as abscissa, and the standard curve was plotted. The regression equation was y = 1.245x + 7.526C, *r* = 0.9996. The standard was repeated for five times with RSD 0.7% to ensure the method was accurate. AOS was measured by using the same situation and the results showed perfect repeatability. The average content of Astragaloside A was 0.216% with RSD 1.5%. The tests were stable at 0, 2, 4, 6, and 8 h.

Patients
--------

Before the experiment, all procedures were approved by the human research ethical committee of the Affiliated Hospital of Changchun University of Traditional Chinese Medicine (Changchun, China, approval no. 20170128x). A written consent form approved by our committee and signed by all subjects. Eighty children with allergic asthma, were recruited at the Department of Pediatrics, Affiliated Hospital of Changchun University of Traditional Chinese Medicine. The clinical diagnostic criteria of the "Children\'s Asthma Diagnosis and Prevention Guide" was used to examine allergic asthma in children ([@B22]), and the children had the following symptoms: wheezing, shortness of breath, chest pain or cough, and allergic asthma caused by cold air, physical and chemical stimulation, viral upper respiratory tract infection and exercise. Wheezing episodes in the lungs could be heard and the expiratory phase was prolonged. The typical clinical manifestations, such as no clear wheezing or signs should have at least the following positive test: bronchial provocation test or motor positive test, and or bronchial diastolic positive test (forced expiratory volume in 1 s FEV1 increased).

Allergy skin test
-----------------

The hypersensitivity response of each patient was assessed by using conventional skin prick tests against 16 common aeroallergens according to an earlier report ([@B23]). Skin prick tests were performed according to the methods introduced by Gislason ([@B24]). The test would be regarded as clinically significant if the allergen reactions were more than 10.

Measurement of total IgE
------------------------

Serum IgE levels were measured by using the Human IgE ELISA Kit from Abcam (Shanghai, China). Serum IgE levels were positively associated with the color intensity of the test and calibrated against the WHO standard for IgE ([@B25]).

The test for allergen-specific IgE
----------------------------------

Allergen-specific IgE was detected in the patients\' serum against HD, *D. pteronyssinus* (DP), *D. farinae* (DF), and *B. tropicalis* (BT) by using the AllergyScreen system and ImmunoCAP 100 system (Amersham Pharmacia Biotech, Uppsala, Sweden). The test was calibrated against the WHO Standard for IgE ranging from 0.35 to 100 KU/L for specific IgE.

Inclusion criteria
------------------

The following inclusion criteria were used:

\(1\) Male or female patients between the ages of 3--12 years; (2) Allergens reactions more than 10. (3)Total serum IgE levels more than 350 IU/mL; (4) competency to perform pulmonary function tests and pulmonary function FEV1 \< 80% predictive value; (5) children not taking the medicine such as aspirin and other drugs that may trigger asthma symptoms within 4 weeks before enrollment; (6) children able to receive treatment under the guardianship of a parent who signed an informed consent form.

Exclusion criteria
------------------

Children who had the following conditions were excluded: (1) various psychiatric disorders; (2) severe congenital heart disease; (3) pneumothorax, pleural effusion, active pulmonary tuberculosis, acute exacerbation within the past month and received emergency treatment; (5) infectious rhinitis and sinusitis; (6) anaphylactic shock or eczema of unknown etiology; (7) received immunotherapy and (8) adverse reactions after enrollment.

Patients grouping
-----------------

The extracts of AM were evaporated to dry, and the residue was dissolved in 10 mL ethanol. AOS was prepared by the 10-fold dilution of AM ethanol solution. Residual petroleum and n-butanol compounds were measured by gas chromatography (Agilent 6890, Agilent Tech., USA) with a flame ionization detecting system. None of the residual compounds were found in the AOS solution.

Based on inclusion and exclusion criteria, 80 children with allergic asthma caused by dust mites were recruited at our hospital from February 2016 to June 2017. The sample size was analyzed by using PASS version 13 (NCSS Statistical Software, Kaysville, UT, USA), and the power of sample size was 85%. The children were evenly and randomly assigned into two groups: the AOS group, where the patients received 10 mL AOS daily and the control group, where the patients received placebo (0.1% quinine chloride in deionized water) daily. The duration of the experiment was 6 months.

Evaluation of allergic asthma symptoms
--------------------------------------

Lung function was measured by using FEV1, which was compared with predicted values. Most symptoms of allergic asthma were investigated by using Pediatric Asthma Quality of Life Questionnaire (PAQLQ) scores as shown in Table [1](#T1){ref-type="table"} ([@B26]).

###### 

The Pediatric Asthma Quality of life questionnaire (PAQLQ score).

  **Scores**             **Aspects**
  ---------------------- --------------------------------------------------------------------------
  **LIMITED ACTIVITY**   
  1                      Strong physical activity
  2                      Medium physical activity
  3                      Social activity
  4                      Work-related activities
  5                      Sleepiness
  **SYMPTOMS**           
  8                      Shortness of breath
  14                     Dull aching chest
  18                     Expiratory or inspiratory difficulties, early morning symptoms of asthma
  24                     Night arousal
  **ENVIRONMENT**        
  9                      Smoke,
  17                     Dust
  23                     Air pollution environment
  26                     Strong smell symptoms,
  25                     Air pollution of the environment
  28                     Strong smell had to be avoided
  **EMOTION**            
  6                      Chest tightness caused by the degree of discomfort
  7                      Worried about suffering from asthma
  12                     Cough caused by discomfort
  13                     Asthma and worry
  15                     Medication
  16                     Clear throat
  21                     Worry about no asthma medication
  22                     Heavy breathing
  27                     Fear of breathlessness
  29                     Remuneration,
  30                     Desperately breathing,
  10                     Limitation of conscious activities

The severity of asthma was classified into four levels according to previous report ([@B27]): mild intermittent, mild persistent, moderate persistent, and severe persistent based on symptom frequency and either spirometric (FEV~1~) or peak expiratory flow (PEF). The primary outcome was also measured according to asthma-related clinical events, including cough, wheeze, and need of intervention. Allergic sensitization to common dietary and respiratory allergens were measured according to an earlier report ([@B28]). Serum IgE of 0.2 or 0.35 IU/mL were regarded as positive and predictive for allergic asthma. Eosinophils ([@B29]) and serum levels of ECP ([@B30]) are increased in allergic asthma.

Measurement of serum levels of IL-10 and TGF-β
----------------------------------------------

Five millimeters of venous blood was obtained from each patient. Two millimeters of blood was placed at room temperature for 1 h. The serum was isolated via centrifugation at 5000 × *g* for 10 min. The serum levels of IL-10 and TGF-β were measured by using the ELISA kits from R & D Systems, Inc. (Minneapolis, MN, USA). The serum Th1 cytokines (IL-2 and IFN-γ), and Th2 cytokines (IL-4 and IL-6) ([@B31]) were measured by using the kits from Abcam (Shanghai office, China).

Measurement of the percentage of gated CD4^+^ T cells, CD4^+^cd25^+^ T cells, CD4^+^cd25^high^ treg cells, CD4^+^cd25^+^ foxP3^+^ treg cells and CD4^+^CD25^high^ CD127^low^ treg cells
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Three millimeters of blood was added to an anticoagulant-containing (EDTA-K2) tube. Peripheral blood mononuclear cells (PBMCs) were isolated from human peripheral blood via Ficoll-Hypaque (Sigma, St. Louis, MO, USA) density gradient centrifugation. Mouse anti-human CD4 monoclonal antibody was purchased from Zhongshan Golden Bridge Biotechnology (Beijing, China) CD127 (BD Pharmingen \#558598, San Jose, CA) was conjugated to ALEXA FLUOR 488. Goat-anti-mouse FITC IgG was purchased from Kangwei (Beijing, China). CD25 PE-Cy7 (BD, clone M-A251), CD25 APC (clone 2A3), and FoxP3 PE (clone PCH101) were purchased from BD Biosciences (Franklin, NJ, USA). CD4+ T cells were gated on side scatter height vs. CD4. The percentage of CD4^+^CD25^+^ T cells, CD4^+^CD25^high^ Treg cells, CD4^+^CD25^+^ FoxP3^+^ Treg cells and CD4^+^CD25^high^CD127^low^ Treg cells in PBMCs was measured by using FACSCalibur flow cytometer (Becton Dickinson, Mountain View, CA, USA).

Statistical analysis
--------------------

SPSS20.0 statistical software was used to perform statistical analyses. All data were expressed as mean values ± standard deviation (S.D.). Normal distribution and variance homogeneity were analyzed by a paired *t*-test. Normal distribution was analyzed by ANOVA between groups. Non-normal distribution was analyzed by Wilcoxon rank test. Count data were compared by using contingency χ^2^ test. The statistical differences were significant if *P* \< 0.05.

Results {#s3}
=======

Recovery rate of astragaloside A
--------------------------------

AOS was taken from six different batches. With two copies per group, each group was added to a concentration of 0.197 mg/mL Astragaloside A control solution 0.8, 1.0, and 1.2 mL. The average recovery rate of Astragaloside A was 96.2% with RSD 2.65% (Table [2](#T2){ref-type="table"}).

###### 

Recovery rate of Astragaloside A.

  **Times**   **Sampling volume/ml**   **Sample content/mg**   **Addition/mg**   **Measured values/mg**   **Recovery rate**   **Average value**   **RSD/%**
  ----------- ------------------------ ----------------------- ----------------- ------------------------ ------------------- ------------------- -----------
  1           10                       0.215                   0.1574            0.35420                  0.9511              0.962               2.65
  2           10                       0.215                   0.1574            0.36540                  0.9812                                  
  3           10                       0.215                   0.1967            0.39870                  0.9684                                  
  4           10                       0.215                   0.1967            0.37540                  0.9118                                  
  5           10                       0.215                   0.2360            0.44670                  0.9905                                  
  6           10                       0.215                   0.2360            0.43650                  0.9678                                  

Average contents of astragaloside a in AOS
------------------------------------------

Table [3](#T3){ref-type="table"} showed that the contents of Astragaloside A were 0.216 ± 0.027 mg/mL from six batches of AOS.

###### 

The average contents of Astragaloside A from 6 batches of AOS.

  **Batches**                          **1**   **2**   **3**   **4**   **5**   **6**
  ------------------------------------ ------- ------- ------- ------- ------- -------
  Contents of Astragaloside A, mg/ml   0.203   0.242   0.213   0.189   0.243   0.204

*AOS, astragalus oral solution*.

Clinical demographic characteristics
------------------------------------

The AOS and control groups were composed of 80 cases with 43 males and 37 females, and aged 3--12 years. Age is associated with the risk of allergic asthma ([@B32], [@B33]). In our study, age distribution (5-7, 8-10, and 11-12) was similar between the two groups (*P* \> 0.05). The experimental group comprised 23 males and 17 females, with an average age of 8.7 ± 3.3 years. The control group comprised 22 males and 18 females, with an average age of 8.9 ± 2.7 years. The statistical difference was not statistically significant in all parameters (Table [4](#T4){ref-type="table"}, *P* \> 0.05). The most allergic responses to common inhalants included *Cocos nucifera, Brassica nigra*, cat dander, HD, DP, DF, and BT. The statistical difference for these inhalants was insignificant between two groups (Table [5](#T5){ref-type="table"}, *P* \> 0.05). The total serum IgE levels were 428.49 ± 58.61 and 431.27± 60.45 IU/mL between two groups. The statistical difference for allergen-specific IgE reactivity against HD, DP, DF, and BT was insignificant between the two groups (Table [6](#T6){ref-type="table"}, *P* \> 0.05).

###### 

Clinical demographic characteristics.

                                **AOS group**   **Control group**   **χ^2^ values or *t* values**   ***P*-values**
  ----------------------------- --------------- ------------------- ------------------------------- ----------------
  Age, years                    8.7 ± 3.3       8.9 ± 2.7           0.124                           0.658
  5-7 year, *n* (%)             6               4                   0.630                           0.730
  8-10 year, *n* (%)            26              29                                                  
  11-12 year, *n* (%)           8               7                                                   
  Male/Female                   23/17           22/18               0.051                           0.822
  BMI                           22.67 ± 3.18    23.98 ± 2.75        0.578                           0.209
  Disease duration, months      36.90 ± 4.28    38.91 ± 5.27        2.397                           0.009
  Respiratory rate, times/min   19.74 ± 1.54    20.33 ± 1.49        −1.908                          0.153
  Heart rate, time/min          76.82 ± 3.77    77.02 ± 3.03        −0.292                          0.768
  Systolic pressure, mmHg       121.68 ± 9.35   123.83 ± 11.55      −1.039                          0.326
  Diastolic pressure, mmHg      77.04 ± 7.11    75.46 ± 6.51        1.127                           0.235

*BMI, body mass index = weight (kg)/height (m^2^)*.

###### 

Allergic response to common inhalants.

                                     **AOS group**   **Control group**   ***P*-values**
  ---------------------------------- --------------- ------------------- ----------------
  Pollens                                                                0.936
  Cocos nucifera                     31 (77.5)       33 (82.5)           
  Brassica nigra                     20 (50)         24 (60)             
  Delonix sp.                        19 (47.5)       17 (42.5)           
  *Azadirachta indica*               17 (42.5)       15 (37.5)           
  *Caesalpinia* sp                   15 (37.5)       18 (45)             
  Molds                                                                  0.915
  *Aspergillus fumigatus*            11 (27.5)       12 (30)             
  *Aspergillus niger*                8 (20)          9 (22.5)            
  *Candida albicans*                 5 (12.5)        4 (10)              
  *Cladosporium* sp.                 6 (15)          7 (17.5)            
  *Alternaria lternate*              4 (10)          2 (5)               
  Others                                                                 0.623
  Dog dander                         6 (15)          9 (22.5)            
  Cat dander                         20 (50)         21 (52.5)           
  House dust                         40 (100)        32 (80)             
  *Dermatophagoides pteronyssinus*   32 (80)         39 (97.5)           
  *Dermatophagoides farinae*         21 (52.5)       19 (47.5)           
  *Blomia tropicalis*                24 (60)         22 (55)             

*Chi-square test was performed and there will be significant difference if P \< 0.05 between two groups*.

###### 

Allergen-specific IgE reactivity against HD, DP, DF, and BT Allergens.

       **AOS group**   **Control group**   ***P*-values**
  ---- --------------- ------------------- ----------------
  HD   28 (70)         25 (62.5)           0.478
  DP   24 (60)         20 (50)             0.369
  DF   30 (75)         33 (82.5)           0.412
  BT   35 (87.5)       28 (70)             0.056

*HD, House dust; DP, D. pteronyssinus; DF, D. farinae; BT, B. tropicalis. Chi-square test was performed and there will be significant difference if P \< 0.05 between two groups*.

No significant differences were found for symptoms of allergic asthma and biochemical characterization of allergic asthma between the two groups (Tables [7](#T7){ref-type="table"}, [8](#T8){ref-type="table"}). Significant differences of asthma-related events were found after 6-month follow-up (Table [7](#T7){ref-type="table"}). The severity of allergic asthma was significantly lower in the experimental group than in the control group (*P* \< 0.05).Similarly, biochemical indices of allergic asthma were significantly lower in the experimental group than in the control group (Table [8](#T8){ref-type="table"}, *P* \< 0.05).

###### 

Comparison of symptoms of allergic asthma between two groups.

                                                  **AOS group, *n* = 40**   **Control group, *n* = 40**   ***P*-values**
  ----------------------------------------------- ------------------------- ----------------------------- ----------------
  **BEFORE THERAPY**                                                                                      
  No. of wheezing episodes                        1.10 (0.7--1.6)           1.08 (0.6--1.5)               0.85
  Days with wheeze                                7.58 (1.36--13.9)         6.95 (0.90--12.3)             0.25
  Days on inhalative betamimetics                 13.8 (3.37--24.6)         13.2 (8.18--17.2)             0.78
  Days on inhalative steroids                     10.0 (7.23--24.9)         9.80 (6.99--17.5)             0.89
  No. of rescue-free days                         128.7 (108.4--158.6)      121.5 (112.0--163.0)          0.93
  No. of symptom-free days                        123.0 (126.4--162.6)      128.5 (115.7--160.3)          0.71
  **Allergic Asthma Classification, Cases (%)**                                                           
  Mild intermittent                               13 (32.5)                 15 (37.5)                     0.968
  Mild persistent                                 12 (30)                   11 (27.5)                     
  Moderate persistent                             8 (20)                    7 (17.5)                      
  Severe persistent                               7 (17.5)                  7 (17.5)                      
  **AFTER THERAPY**                                                                                       
  No. of wheezing episodes                        0.51 (0.3--1.9)           1.10 (0.6--1.9)               0.03
  Days with wheeze                                5.26 (3.03--13.7)         11.3 (7.15--14.8)             0.01
  Days on inhalative betamimetics                 10.7 (6.3--30.2)          13.9 (2.68--18.9)             0.02
  Days on inhalative steroids                     10.5 (6.3--22.7)          14.8 (4.6--25.6)              0.01
  No. of rescue-free days                         148.5 (108.9--168.1)      126.0 (99.6--172.4)           0.02
  No. of symptom-free days                        142.5 (102.6--152.5)      104.0 (86.2--141.8)           
  **Allergic Asthma Classification, Cases (%)**                                                           
  Mild intermittent                               21 (52.5)                 12 (30)                       0.02
  Mild persistent                                 10 (2.5)                  6 (1.5)                       
  Moderate persistent                             4 (10)                    14 (3.5)                      
  Severe persistent                               5 (12.5)                  8 (20)                        

*The statistical difference was significant if P \< 0.05*.

###### 

Comparison of biochemical characterization of allergic asthma between two groups.

                       **AOS group, *n* = 40**   **Control group, *n* = 40**   ***P*-values**
  -------------------- ------------------------- ----------------------------- ----------------
  **BEFORE THERAPY**                                                           
  Total IgE (IU/mL)    416.7 (312.8--556.4)      412.2 (310.0--560.6)          0.86
  Eosinophils (%)      2.6 (2.3--3.9)            2.8 (2.3--3.5)                0.32
  ECP (μg/mL)          22.3 (14.9--29.9)         21.9 (12.6--28.2)             0.69
  **AFTER THERAPY**                                                            
  Total IgE (IU/mL)    214.7 (162.3--290.5)      420.2 (316.2--481.3)          0.01
  Eosinophils (%)      2.2 (1.5--4.0)            3.0 (2.5--3.6)                0.01
  ECP (μg/mL)          16.7 (9.89--23.8)         24.8 (16.6--32.4)             0.01

*The statistical difference was significant if P \< 0.05*.

AOS treatment improved the allergic asthma symptoms in children
---------------------------------------------------------------

Before treatment, the FEV1% in the AOS group was comparable with that in the control group (*P* \> 0.05, Figure [1A](#F1){ref-type="fig"}). After treatment, the FEV1% were significantly increased in the AOS group than in the control group (*P* \< 0.05, Figure [1A](#F1){ref-type="fig"}). Similarly, PAQLQ scores were comparable between two groups before treatment (*P* \> 0.05, Figure [1B](#F1){ref-type="fig"}). After treatment, PAQLQ scores were increased significantly in the AOS group when compared with those in the control group (*P* \< 0.05, Figure [1B](#F1){ref-type="fig"}). The results suggest that AOS reduces the symptoms of allergic asthma by improving FEV1% and PAQLQ.

![The effects of AOS on FEV1% and PAQLQ scores in the children with allergy asthma. **(A)** The effects of AOS on FEV1% in the children with allergy asthma. **(B)** The effects of AOS on PAQLQ scores in the children with allergy asthma. FEV1, forced expiratory volume in 1 s; PAQLQ, Pediatric Asthma Quality of Life Questionnaire. *n* = 40 for each group. The statistical difference was significant for *P* \< 0.05.](fped-06-00255-g0001){#F1}

AOS increased the serum level of IL-10 and reduced the level of TGF-β
---------------------------------------------------------------------

The serum levels of IL-10 were comparable between the AOS (24.12 ± 3.68 pg/mL) and control groups (26.25 ± 3.79 pg/mL) (Figure [2A](#F2){ref-type="fig"}, *P* \> 0.05). Comparatively, the serum levels of TGF-β were same between the AOS (932.67 ± 148.43 pg/mL) and control groups (968.27 ± 150.64 pg/mL) (Figure [2B](#F2){ref-type="fig"}, *P* \> 0.05). After treatment, the serum level of IL-10 in the experimental group was significantly increased and the level of TGF-β was significantly decreased compared with those in the control group (Figure [2](#F2){ref-type="fig"}, *P* \< 0.05). The results suggest that AOS treatment increases the serum levels of IL-10 and reduces the levels of TGF-β.

![The effects of AOS on the serum levels of IL-10 and TGF-β in the children with allergy asthma. **(A)** The effects of AOS on serum level of IL-10 in the children with allergy asthma. **(B)** The effects of AOS on TGF-β in the children with allergy asthma. *n* = 40 for each group. The statistical difference was significant for *P* \< 0.05.](fped-06-00255-g0002){#F2}

AOS treatment reduced serum level of th1 (IL-2 and IFN-γ) and th2 cytokines (IL-4 and IL-6)
-------------------------------------------------------------------------------------------

Before the treatment, the statistical difference for the serum level of Th1 (IL-2, Figure [3A](#F3){ref-type="fig"}, and IFN-γ, Figure [3D](#F3){ref-type="fig"}) and Th2 cytokines (IL-4, Figure [3B](#F3){ref-type="fig"} and IL-6, Figure [3C](#F3){ref-type="fig"}) was insignificant between AOS and control groups (*P* \> 0.05). After the treatment, the serum levels of Th1 (IL-2, Figure [3A](#F3){ref-type="fig"}, and IFN-γ, Figure [3D](#F3){ref-type="fig"}) and Th2 cytokines (IL-4, Figure [3B](#F3){ref-type="fig"} and IL-6, Figure [3C](#F3){ref-type="fig"}) were lower in the AOS group than the control group (*P* \< 0.05).

![The effects of AOS on the serum levels of Serum Th1 cytokines (IL-2 and IFN-γ), and Th2 cytokines (IL-4 and IL-6). **(A)** The effects of AOS on serum level of IL-2. **(B)** The effects of AOS on serum level of IL-4. **(C)** The effects of AOS on serum level of IL-2. **(B)** The effects of AOS on serum level of IL-6. **(D)** The effects of AOS on serum level of IFN-γ. *n* = 40 for each group. The statistical difference was significant for *P* \< 0.05.](fped-06-00255-g0003){#F3}

Percentage of gated CD4^+^ T cells, CD4^+^CD25^+^ T cells, CD4^+^CD25^high^, CD4^+^CD25^+^foxP3^+^ treg cells and CD4^+^CD25^high^CD127^low^ treg cells
-------------------------------------------------------------------------------------------------------------------------------------------------------

Before treatment, the percentage of gated CD4^+^ T cells (14.26 ± 3.51%, Figure [4A](#F4){ref-type="fig"}), CD4^+^CD25^+^ T cells (9.15 ± 2.28%, Figure [4B](#F4){ref-type="fig"}), CD4^+^CD25^high^ (5.67 ± 0.75%, Figure [4C](#F4){ref-type="fig"}), CD4^+^CD25^+^FoxP3^+^ Treg cells (1.53 ± 0.21%, Figure [4D](#F4){ref-type="fig"}), and CD4^+^CD25^high^CD127^low^ (0.72 ± 0.28%, Figure [4E](#F4){ref-type="fig"}) Treg cells in the AOS group were comparable with those in the control group, gated CD4^+^ T cells (13.89 ± 4.01%, Figure [4A](#F4){ref-type="fig"}), CD4^+^CD25^+^ T cells (9.29 ± 2.37%, Figure [4B](#F4){ref-type="fig"}), CD4^+^CD25^high^ (5.38 ± 0.64%, Figure [4C](#F4){ref-type="fig"}), CD4^+^CD25^+^FoxP3^+^ Treg cells (1.62 ± 0.30%, Figure [4D](#F4){ref-type="fig"}), and CD4^+^CD25^high^CD127^low^ (0.79 ± 0.25%, Figure [4E](#F4){ref-type="fig"}) (*P* \> 0.05). After treatment, the percentage of gated CD4^+^ T cells (18.63 ± 6.27%, Figure [4A](#F4){ref-type="fig"}), CD4^+^CD25^+^ T cells (12.34 ± 4.61%, Figure [4B](#F4){ref-type="fig"}), CD4^+^CD25^high^ (9.65 ± 0.83%, Figure [4C](#F4){ref-type="fig"}), CD4^+^CD25^+^FoxP3^+^ Treg cells (2.46 ± 0.37%, Figure [4D](#F4){ref-type="fig"}) and CD4^+^CD25^high^CD127^low^ (1.34 ± 0.31%, Figure [4E](#F4){ref-type="fig"}) Treg cells in the AOS group were significantly higher than those in the control group, gated CD4^+^ T cells (13.99 ± 4.22%, Figure [4A](#F4){ref-type="fig"}), CD4^+^CD25^+^ T cells (9.12 ± 2.05%, Figure [4B](#F4){ref-type="fig"}), CD4^+^CD25^high^ (5.63 ± 0.47%, Figure [4C](#F4){ref-type="fig"}), CD4^+^CD25^+^FoxP3^+^ Treg cells (1.58 ± 0.24%, Figure [4D](#F4){ref-type="fig"}), and CD4^+^CD25^high^CD127^low^ (0.81 ± 0.28%, Figure [4E](#F4){ref-type="fig"}) (*P* \< 0.05) (*P* \< 0.05). The results suggest that AOS consumption increases the percentage of gated CD4^+^ T cells, CD4^+^CD25^+^ T cells, CD4^+^CD25^high^, CD4^+^CD25^+^FoxP3^+^ Treg cells, and CD4^+^CD25^high^CD127^low^ Treg cells in children with allergic asthma.

![The effects of AOS on the contents of T cells in the children with allergy asthma. **(A)** The effects of AOS on the contents of gated CD4^+^ T cells in the children with allergy asthma. **(B)** The effects of AOS on the contents of CD4^+^CD25^+^ T cells in the children with allergy asthma. **(C)** The effects of AOS on the contents of CD4^+^CD25^high^ Treg cells in the children with allergy asthma. **(D)** The effects of AOS on the contents of CD4^+^CD25^+^FoxP3 Treg cells in the children with allergy asthma. **(E)** The effects of AOS on the contents of CD4^+^CD25^high^CD127^low^ Treg cells in the children with allergy asthma. *n* = 40 for each group. The statistical difference was significant for *P* \< 0.05.](fped-06-00255-g0004){#F4}

Discussion {#s4}
==========

The results showed that the content of Astragaloside A in AOS varied from 0.19 to 0.24 mg/mL. The quality of the different batches of the mixture was influenced by the quality of the decoction pieces, processing and other factors. HPLC was an effective method to detect the quality of AOS and provided a basis for high-quality standards.

Allergic asthma is caused by a variety of cells, including inflammatory cells (neutrophils, T lymphocytes, eosinophils, and mast cells) ([@B34]), airway structural cells (airway smooth muscle cells and epithelial cells) ([@B35]), and cell components. AR is the most common symptoms of allergic asthma after individuals come in contact with allergens. Many inflammatory cells and cytokinesare involved in the inflammatory responses, including nasal itching, sneezing, running nose, and stuffy nose. The incidence of childhood allergic asthma has been increasing, but its pathogenesis is not yet clear. The traditional Th1/Th2 imbalance theory cannot explain all the pathogenesis. Presently, a number of studies have focused on Treg cells to investigate the pathognesis ([@B36], [@B37]). Our findings demonstrated that AOS treatment reduced the serum levels of Th1 and Th2 cytokines (Figure [3](#F3){ref-type="fig"}). Analyses of childhood allergic asthma by using CD4^+^CD25^high^CD127^low^ Treg cells will have important clinical values.

IL-10 regulates allergic asthma and is directly involved in the regulation of inflammatory cells. IL-10 factor can inhibit the proliferation, secretion of Th cells, and the proliferation and differentiation of antigen-presenting cells ([@B38]). IL-10 cells inhibit T cells, antigen presentation ([@B39]), and the expression of IL-8 ([@B40]). IL-10 was reported to inhibit eosinophil-induced inflammatory effects of asthma, suggesting that IL-10 plays a key negative regulatory role in the development of allergic asthma ([@B41]). The level of IL-10 was found to be reduced significantly in T cells of peripheral blood during the onset of allergic asthma ([@B42]). In our study, the IL-10 level in the AOS group was comparable with that in control group before treatment (*P* \> 0.05, Figure [2](#F2){ref-type="fig"}). After treatment, the level of IL-10 in the AOS group was significantly increased (*P* \< 0.05). After AOS treatment, IL-10 may inhibit the antigen-presenting process and T cells response and play a critical role in the prevention of asthma.

TGF-β is a kind of stimulating factor with many biological effects, and it plays a critical role in regulating inflammation in various organs and tissues. Thus, TGF-β is widely studied in the transforming growth factor family and involved in the fibrosis formation of tissues and organs. Its overexpression in cardiac tissue can cause cardiac hypertrophy or myocardial fibrosis, which is involved in the process of ventricular remodeling ([@B43], [@B44]). TGF-β is a multifunctional cytokine that can participate in the process of cell proliferation, apoptosis and differentiation ([@B45]). In the immune system, TGF-β is a regulator of immunity with both pro- and anti-inflammatory effects and is involved in a variety of airway inflammation and immune responses. Many studies on TGF-β in the pathogenesis of asthma have been performed. However, t many controversies at different stages of development are still present. Most of researchers think that TGF-β can inhibit or promote inflammation ([@B46], [@B47]).

Elevated levels of TGF-β were reported in patients with atopic asthma ([@B48], [@B49]), which may be caused by the continued stimulation of allergens and airway remodeling. TGF-β also has a chemotactic function and can promote the proliferation and differentiation of inflammatory cytokines ([@B50]). In previous studies, the severity of asthma was found to be related to the concentration of TGF-β in the peripheral blood ([@B51]). In the present study, the serum level of TGF-β in the experimental group was comparable with that in the control group (*P* \> 0.05). After AOS consumption, the level of TGF-β was significantly decreased (*P* \< 0.05), suggesting that AOS ameliorates allergic asthma by reducing the serum level of TGF-β.

Treg cells are a subset of T-cells that control the autoimmune reactivity *in vivo* and play a key role in the inhibition of autoimmunity ([@B52], [@B53]). They exert immunosuppressive effects through the specific binding of their surface molecules (CTLA-4, CD25) to the corresponding ligands on the cells ([@B54]). IL-10 can inhibit the proliferation of T cells, the synthesis of cytokines such as IL-2 by Th1 and Th2 cells, and the expression of MHCII in macrophages ([@B55]). Immune regulatory T cells may maintain the immune tolerance via several mechanisms. CD4^+^CD25^+^ Treg cells are able to bind to target cells and participate in immune regulation. In previous studies, CD4^+^CD25^+^ Treg cells and CD4^+^CD25^+^ T cells were increased simultaneously with CD4^+^CD25^+^ Treg proliferation ([@B56]). The percentage of CD4^+^CD25^+^ T cells and CD4^+^CD25^high^CD127^low^ was decreased during acute episode of childhood allergic asthma ([@B57]). In the present study, the percentage was comparable for CD4^+^CD25^+^ T cells, CD4^+^CD25^high^, CD4^+^CD25^+^FoxP3^+^ Treg cells and CD4^+^CD25^high^CD127^low^ Treg cells between two groups before the treatment (Figure [4](#F4){ref-type="fig"}, *P* \> 0.05). After the treatment, AOS consumption increased the percentage of CD4^+^CD25^+^ T cells, CD4^+^CD25^high^, CD4^+^CD25^+^FoxP3^+^ Treg cells and CD4^+^CD25^high^CD127^low^ Treg cells (Figure [4](#F4){ref-type="fig"}, *P* \< 0.05). The results suggest AOS consumption reduces the risk of allergic asthma by increasing the percentage of CD4^+^CD25^+^ T cells, CD4^+^CD25^high^, CD4^+^CD25^+^FoxP3^+^ Treg cells and CD4^+^CD25^high^CD127^low^ Treg cells in PBMCs.

Th2 cytokines are associated with allergic airway inflammation ([@B2]) while Th1 cells inhibit Th2 immune activities ([@B3]). The imbalance of Th1/Th2 cytokines indicates the risk of asthma ([@B58]). Peripheral blood eosinophils increase the levels of Th1 and Th2 cytokines ([@B4]). By contrast, AOS therapy will reduce the levels of peripheral blood eosinophils and may result in the down-regulation of Th1 and Th2 cytokines. AOS may also increase the level of Treg cells, which will suppress the level of blood eosinophils ([@B5]).

The present study has some limitations to. For the side effects of AOS were still unclear. According to previous reports, *Astragalus* induces some side effects, including anemia, neutropenia, thrombocytopenia, fatigue, poor appetite, nausea, and vomiting ([@B1]). However, these side effects were not found in the present study. Although Astragaloside A is the main bioactive component in AOS, other components were not analyzed in AOS. The functions of certain components should be confirmed in the future work. In this experiment, we only explored the effects of AOS on the serum levels of IL-10, TGF-β and the percentage of CD4^+^CD25^+^ T cells, CD4^+^CD25^high^, CD4^+^CD25^+^FoxP3^+^ Treg cells and CD4^+^CD25^high^CD127^low^ Treg cells in PBMCs. However, modern studies show that the expression level of Treg cells is associated with a variety of autoimmune diseases. The study of Treg alone cannot fully explain the exact mechanism for its action. In recent years, the research on the immune balance between Treg/Th17 has been increased. In the future, further work is highly demanded to reveal the relationship between the impact of the balance and allergic asthma in children.

Conclusions {#s5}
===========

The average contents of Astragaloside A were 0.216 ± 0.027 mg/mL from six batches of AOS. After 6-month therapy, AOS treatment was more effective in the experimental group than in the control group (*P* \< 0.05). AOS reduced the symptoms of allergy asthma in children group by improving FEV1% and PAQLQ scores. The children with allergic asthma have a lower level of serum IL-10 and higher level of TGF-β. AOS consumption increased the level of serum IL-10 and reduced the level of TGF-β. AOS can be effective in the treatment of allergic asthma in children by increasing the percentage of CD4^+^CD25^+^ T cells, CD4^+^CD25^high^, CD4^+^CD25^+^FoxP3^+^ Treg cells, and CD4^+^CD25^high^CD127^low^ Treg cells.
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